Calidi Biotherapeutics, Inc. Deferred State and Local Income Tax Expense (Benefit)
Calidi Biotherapeutics, Inc. (CLDI) reported Deferred State and Local Income Tax Expense (Benefit) of -$208.09 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2023-03-31
- Calidi Biotherapeutics, Inc. deferred state and local income tax expense (benefit) for fiscal 2022 was -$208.09K.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 9 month | Deferred State and Local Income Tax Expense (Benefit) 12 month |
|---|---|---|
| 2022-12-31 | -$208.09K 10-K · filed 2023-03-31 | |
| 2021-12-31 | -$84.23K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |